IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or metastatic colorectal cancer.

本研究的主要目的为评估IBI310联合信迪利单抗（sintilimab）治疗微卫星高度不稳定（MSI-H）或错配修复缺陷（dMMR）的局部进展期或转移性结直肠癌患者的有效性与安全性。